Home > Resources > Whitepapers > Discovering Effective Strategies for Sales and Marketing in the Face of Reduced Access to Oncologists

Research, PHARMA TECH

Discovering Effective Strategies for Sales and Marketing in the Face of Reduced Access to Oncologists

January 15, 2023

Oncology breakthroughs are currently fueling significant
growth in the market, as well as the competition between
pharmaceutical brands for market share. As increasingly
individualized cancer treatments become available,

Spotlight

Laboratorios Gebro Pharma

Laboratorios Gebro Pharma, SA, a Spanish subsidiary of the Austrian company Gebro Pharma GmbH, was established in March 2002, establishing its headquarters in Barcelona, and focused its main activity on the development and commercialization of treatments against pain and inflammation, making its way quickly in the areas of Rheumatology, Pain Units and Hospitals. Currently, Laboratorios Gebro Pharma is a company in full expansion, which has successful experiences in co-promotion and comarketing, with a team of more than 100 professionals and whose growth is one of the most outstanding in the Spanish pharmaceutical market in terms of billing and commercial coverage. .

OTHER WHITEPAPERS

QbD and PAT in Biopharmaceutical Development

whitePaper | July 12, 2022

As the pharmaceutical industry tries to embrace the methodologies of quality by design (QbD) provided by the FDA ’s process validation (PV) guidance (1) and International Conference on Harmonization.

Multi-channel clinical trial recruitment technology checklist

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

A pragmatic approach to developing rare disease drug

whitePaper | July 13, 2023

Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.

Advancing drug development using in silico modeling

whitePaper | June 22, 2022

The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture.

Ultrasafe film Ultra-high barrier Product stability Patient safety

whitePaper | December 22, 2022

Every viable pharmaceutical packaging system must comprise materials proven to protect its contents against moisture and other atmospheric variables, and be safe for use with the specified dosage form and the route of administration1